Clinical trials: Respiratory Therapy
Pulmonary Disease, Chronic Obstructive
Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease
Batefenterol inhalation powder is currently under development as a fixed-dose combination with fluticasone furoate (FF) for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02573870
- Testing
- Batefenterol + Fluticasone Furoate, Albuterol
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma
The purpose of this study is to evaluate the safety and effectiveness of once daily oral administration of JNJ-39758979 in the treatment of adults (18 to 65 years of age) with persistent asthma.
- Trial name
- NCT00946569
- Testing
- JNJ39758979
- Where
- 24 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pneumonia, Pneumococcal, Community Acquired Infections
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Trial name
- NCT00035269
- Testing
- Antibiotic
- Where
- 46 sites in United States, Slovakia and 2 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned.
- Trial name
- NCT06465329
- Testing
- Cemiplimab, Platinum-based chemotherapy, REGN7075
- Where
- 47 sites in United States, Brazil and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Asthma
Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or…
- Trial name
- NCT03373045
- Where
- 175 sites in United States, Puerto Rico
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80%-85% of lung cancers cases. Squamous carcinoma accounts for 20-30% of all NSCLC cases.
- Trial name
- NCT07756645
- Testing
- ABBV-1480, Pembrolizumab, Carboplatin
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 940 people
- Sponsor
- AbbVie
Rhinitis, Allergic, Perennial
Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)
The primary objective of the study was to characterize the difference in prepubescent growth velocity in children 3 to 9 years of age with perennial allergic rhinitis (PAR) treated with triamcinolone acetonide (TAA) nasal spray…
- Trial name
- NCT00449072
- Testing
- TAA-AQ, Nasacort® AQ, Claritin®
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in…
- Trial name
- PACIFIC-8 (NCT05211895)
- Testing
- Durvalumab, Domvanalimab
- Where
- 226 sites in United States, Belgium and 26 more
- Volunteers
- 791 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer (NSCLC)
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
- Trial name
- NCT00850577
- Testing
- Paclitaxel, Carboplatin, CT-322
- Where
- 55 sites in United States, Brazil and 6 more
- Volunteers
- 255 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Non-small-cell Lung
Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)
The purpose of this trial is to study how long patients can remain progression free when they receive CP-675,206, compared to how long patients can remain progression free when they receive best supportive care.
- Trial name
- NCT00312975
- Testing
- CP-675,206, best supportive care
- Where
- 26 sites in United States, Canada and 3 more
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
Asthma
An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma
Asthma is a chronic inflammatory disease of airways and lungs that results in hyper-reactivity and clinically relevant episodes of wheezing.
- Trial name
- NCT03478657
- Testing
- ELLIPTA DPI, Ease of use questionnaires
- Where
- 19 sites in United States, Canada
- Volunteers
- 222 people
- Sponsor
- GlaxoSmithKline
Ventilation Therapy; Complications
Diaphragmatic Mobility In Ventilated Assisted Patients
The study was a randomized controlled trial. A total of 24 patients who met the inclusion criteria were included in this study and randomly divided by sealed envelope method into Experimental and Control groups with 12 patients…
- Trial name
- NCT04733261
- Testing
- Diaphragmatic mobility, Chest Physiotherapy
- Where
- Pakistan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Aqua Medical Services (Pvt) Ltd
Lung Transplant
Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients
Currently there are no approved therapies for lung transplant recipients in the United States (US). Treatment with CIS following lung transplantation has previously been demonstrated to result in a clinically meaningful…
- Trial name
- NCT00633373
- Testing
- Cyclosporine Inhalation Solution
- Where
- 8 sites in United States
- Sponsor
- APT Pharmaceuticals, Inc.
Cystic Fibrosis
A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
This is a Phase 4, randomized, double-blind, placebo-controlled, parallel-group study in subjects aged 12 years and older with CF who are homozygous for the F508del-CFTR mutation.
- Trial name
- NCT02875366
- Testing
- LUM/IVA
- Where
- 12 sites in Australia, United Kingdom
- Volunteers
- 70 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Small Cell Lung Carcinoma
RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer
This is a study to investigate the potential clinical benefit of roniciclib when given in combination with chemotherapy Carboplatin / Etoposide or Cisplatin / Etoposide as first line treatment in patients with extensive disease…
- Trial name
- CONCEPT-SCLC (NCT02161419)
- Testing
- Roniciclib (BAY1000394)
- Where
- 32 sites in United States, Belgium and 7 more
- Volunteers
- 142 people
- Sponsor
- Bayer
Obstructive Sleep Apnea
Evaluation of a Novel Auto-Adjusting Positive Airway Pressure Algorithm for the Treatment of Obstructive Sleep Apnea Clinical Study
This study aims to assess the effectiveness of an investigational algorithm in the treatment of obstructive sleep apnea.
- Trial name
- NCT06769607
- Testing
- Investigational algorithm, Control algorithm
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- ResMed
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
Study of XB010 in Subjects With Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT06545331
- Testing
- XB010, Pembrolizumab
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 396 people
- Sponsor
- Exelixis
Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia
DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP)
The purpose of this study is to demonstrate the non-inferiority of pafuramidine maleate (DB289)versus trimethoprim-sulfamethoxazole (TMP-SMX)for the treatment of mild to moderately severe Pneumocystis pneumonia (PCP).
- Conditions
- Pneumonia, Interstitial Plasma Cell, Pneumocystis Carinii Pneumonia, Pneumonia, Pneumocystis Carinii, HIV Infections
- Trial name
- NCT00302341
- Testing
- Pafuramidine maleate (DB289), Trimethoprim-Sulfamethoxazole (TMP-SMX)
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Immtech Pharmaceuticals, Inc
Pulmonary Arterial Hypertension
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil…
- Trial name
- TRITON (NCT02558231)
- Testing
- Macitentan, Tadalafil, Selexipag
- Where
- 58 sites in United States, Australia and 13 more
- Volunteers
- 247 people
- Sponsor
- Actelion
Sleep Apnea
Janus II Feasibility
The objectives of this study are to evaluate the feasibility of the remedē® Dual Channel System at implant and overnight sleep studies and to assess chronic safety.
- Trial name
- NCT06556693
- Testing
- Dual Channel Stimulation
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Zoll Medical Corporation